Short answer
Lucid Diagnostics Inc. (LUCD) filed its Q2 2026 10-Q quarterly report on Aug 12, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $1M (up 26.7% year over year) with net income of −$12M.
Q2 2026 key financials · XBRL
- Revenue
- $1M
- +26.7% YoY · +17.4% QoQ
- Net income
- −$12M
- −163.3% YoY · +16.0% QoQ
- Operating margin
- -868.4%
- EPS (diluted)
- −$0.07
- +58.8% QoQ
Source: XBRL data from the Lucid Diagnostics Inc. (LUCD) Q2 2026 10-Q on SEC EDGAR. USD.
Lucid Diagnostics Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q2 revenue $1.5M vs $1.2M, up $0.3M YoY, driven by EsoGuard test consideration
- Q2 gross margin 6.7% vs negative 25.0% YoY, with cost of revenue $1.4M vs $1.5M
- EsoGuard remained the sole commercial product; revenue increased $0.3M YoY
- Cash $33.4M at June 30; six-month operating cash use $23.4M and financing cash inflow $22.3M
- April offering netted $16.8M; management expects recurring losses and negative operating cash flow, requiring additional financing and reimbursement expansion
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Lucid Diagnostics Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.